A study of 11,407 patients found that increased adherence to controller therapies like Pulmicort Respules resulted in a 23.2% decrease in exacerbations among more adherent patients compared to 16.8%. This translates to fewer ER visits and improved asthma control for children with asthma.
A multicenter study found that esomeprazole maintained a pH of greater than 4.0 for 17.8 hours, while lansoprazole and pantoprazole did not match this duration. The study also showed that long-term NSAID use increases the risk of stomach ulcers.
A survey of 1908 participants with gastroesophageal reflux disease (GERD) in Europe and the US found that nearly half experience sleep problems, impacting work and personal lives. The study suggests that GERD symptoms can be related to other health conditions like depression and anxiety.
A new study has found that the use of budesonide reduces the risk of asthma-related events by 40% in children. The study, which involved nearly 2,000 children with mild persistent asthma, showed that earlier treatment with budesonide resulted in fewer exacerbations and improved lung function.
A retrospective cohort study found that early treatment with nebulized ICS reduced hospitalization rates among young children with asthma. The study evaluated 11,407 patients and showed that those receiving initial therapy had lower exacerbation rates.
A new study reveals that patients with asthma experiencing high variability in disease symptoms incur greater direct and indirect costs, including hospitalizations, emergency visits, and lost productivity. High variability patients also report more frequent unscheduled doctor visits and asthma interrupts daily activities more often.
A new study shows that VELCADE (bortezomib) can significantly extend survival and induce important responses in relapsed and refractory multiple myeloma patients. The median overall survival was 17.2 months, with a 14.1-month duration of response and 15.3-month time to disease progression.
A randomized double-blind cross-over study involving 22 healthy volunteers found that Malarone(TM) had no significant effect on vigilance, alertness, or quality of sleep. The results support previous studies showing Malarone(TM) has no impact under normal pressure conditions.
A phase 3 study found Enbrel inhibited radiographic progression in patients with active psoriatic arthritis. The drug reduced the progression of bone erosions and joint space narrowing associated with the disease.
A long-term study of Enbrel found that it effectively treated rheumatoid arthritis (RA) for up to five years, with 71% of patients achieving the ACR 20 response. The medication was also well-tolerated, with no increased rate of serious adverse events or infections compared to placebo.
A Phase 2 double-blind, placebo-controlled study found that 40 patients with ankylosing spondylitis achieved a significant clinical response when treated with ENBREL (etanercept), with 80% of patients showing improvement in outcome measures. The treatment was generally well-tolerated with no serious adverse events or withdrawals.
Phase 3 results of ENBREL (etanercept) demonstrated significant improvement in signs and symptoms of psoriatic arthritis, with 72% of patients experiencing treatment response after 12 weeks. The study also showed improvements in skin manifestations and psoriasis activity.
Dr. John Craig Venter and Professor Edward Wilson were awarded the Science prize for their work in biology, while Dr. Cynthia Kenyon won the Medicine prize for her research on aging. Their discoveries have led to significant advancements in understanding human genomes and developing hormone-based treatments.